Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 294
- Registration Number
- NCT05489848
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 632
- Registration Number
- NCT05487391
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai. China, Shanghai, China
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Okayama University
- Target Recruit Count
- 23
- Registration Number
- NCT05485766
- Locations
- 🇯🇵
St. Luke's International Hospital, Tokyo, Japan
🇯🇵Aichi Cancer Center, Nagoya, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05482893
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT05459129
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇦🇺Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT05446870
- Locations
- 🇨🇳
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan
🇪🇸Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 30
- Registration Number
- NCT05420948
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT05420636
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
- Conditions
- Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Serous AdenocarcinomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal Serous AdenocarcinomaStage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 45
- Registration Number
- NCT05415709
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 130
- Registration Number
- NCT05411237
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.